AARTI DRUGS LTD. - 524348 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), we hereby inform you that the Company has received information from Link Intime India Private Limited, Registrar & Share Transfer Agent of the Company for Loss of share certificates. AARTI DRUGS LTD. - 524348 - Board Meeting Intimation for Consider, Approve And Take On Record Audited Financial Results For The Quarter And Nine Months Ended December 31, 2021 And Consider And Declare Interim Dividend For The FY 2021-22, If Any.
AARTI DRUGS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/01/2022 ,inter alia, to consider and approve and take on record Audited Financial Results for the Quarter and Nine months ended December 31, 2021 and consider and declare Interim dividend for the FY 2021-22, if any. AARTI DRUGS LTD. - 524348 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), we inform you that the Company has issued Duplicate share certificates in lieu of original share certificates. AARTI DRUGS LTD. - 524348 - Shareholding for the Period Ended December 31, 2021
Aarti Drugs Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2021. For more details, kindly Click here AARTI DRUGS LTD. - 524348 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Please find enclose herewith a Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended December 31, 2021 received from Link Intime India Private Limited, Registrar and Share Transfer Agent of our Company. AARTI DRUGS LTD. - 524348 - Statement Of Investor Complaints For The Quarter Ended December 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- RUSHIKESH V DEOLEDesignation :- Company Secretary and Compliance Officer AARTI DRUGS LTD. - 524348 - Closure of Trading Window
This is to inform that the Trading Window of the Company will remain closed from Saturday, January 1, 2022 until the expiry of 48 hours after the declaration of Financial Results of the Company for the quarter and nine months ended December 31, 2021. AARTI DRUGS LTD. - 524348 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), we inform you that the Company has issued Duplicate share certificates in lieu of original share certificates AARTI DRUGS LTD. - 524348 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), we inform you that the Company has issued Duplicate share certificates in lieu of original share certificates AARTI DRUGS LTD. - 524348 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to the provisions of Regulation 30(6) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the officials of the Company will be attending the Investor Conference